Cycling Recovery Peptides Around Injuries, Not Calendars

Your Injury Dictates the Cycle, Not the Calendar

A common mistake in community protocols is cycling recovery peptides like BPC-157 and TB-500 the way lifters run a testosterone enanthate (Test-E) cycle: a rigid 12-week plan with a predetermined post-cycle therapy (PCT) phase, followed no matter what.

Steroid cycles need PCT because outside testosterone shuts down the body's own production. Growth hormone secretagogues have a smaller version of that problem. In a 16-week study of twice-daily hexarelin in 12 healthy older adults, the growth hormone response fell to about half of baseline, then recovered when hexarelin was given again four weeks after stopping. Nobody has shown that BPC-157 or TB-500 suppresses a hormone axis or loses effect with repeated use. So most user protocols treat them as tools for a specific job, tissue repair, and time them around the injury. You don't call the fire department on a weekly schedule; you call them when there's a fire.

The evidence behind all of this is thin. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 35 preclinical studies, one clinical study and "no clinical safety data". As of October 2026, FDA says it has found no human exposure data for the TB-500 fragment. Every dose below comes from user reports and vendor guidance, not trials.

User guides handle an acute tear differently from a chronic tendinopathy or a brutal Smolov squat cycle, so each gets its own section here.

The Acute Injury Protocol

This is for when something gives: a pop in your pec during a heavy bench, or a hamstring that grabs on a deadlift. Community protocols for fresh, significant soft tissue trauma start early, aiming to manage inflammation and kickstart angiogenesis (the formation of new blood vessels). That idea comes from animal work, such as a 2003 rat study in which daily BPC-157 improved healing of transected Achilles tendons over 14 days.

The classic BPC-157 and TB-500 stack is the usual choice here. User guides cast BPC-157 as the local foreman and TB-500 as a systemic coordinator, based on lab research showing that thymosin beta-4 binds actin and promotes cell migration. But TB-500 is a short fragment (LKKTETQ) of that protein, and most of the research used the full protein. No controlled study has tested the two peptides together. Many users inject BPC-157 near the injury, though the rat tendon study used intraperitoneal injection and no human trial has compared sites.

Rather than a steady dose for weeks, a common community pattern front-loads TB-500, then tapers it while BPC-157 continues.

A Practical Acute Injury Timeline

This is one version of that pattern as users describe it, not a tested protocol. Forum reports commonly run 250-500 mcg of BPC-157 once or twice daily (some go to 1-2 mg/day for injuries) and 2-5 mg of TB-500 twice weekly.

The Chronic Nagging Injury Protocol

A lifter's elbow that has ached for nine months, or a patellar tendon that flares after every leg day, isn't a fresh fire; it's a smoldering one. User guides generally treat the high-dose acute protocol as wasted here.

Chronic injuries are characterized by stalled healing, poor blood flow, and disorganized collagen, so the community goal is a sustained, low-level signal rather than a big initial response. In these protocols BPC-157 is the main peptide, and TB-500 is an optional add-on.

The protocol users report is simpler: lower dose, longer duration.

• Peptide: BPC-157 (often solo)
• Dose reported: 250mcg, twice daily
• Duration reported: 8-12 weeks, sometimes longer

The reasoning in these guides is that laying down new, organized collagen takes months, and a higher dose may not work any better while costing more. No study has tested that in people, and runs past 12 weeks go beyond the 4-12 weeks vendor guidance gives. Our page on long-term effects on muscle recovery covers what sustained use might mean.

Prophylactic Use: Is It Prevention or Just Damage Control?

"Preventive" oversells these cycles: no study shows BPC-157 makes healthy tendons more resistant to injury. Some users prefer the term "mitigation cycling" for a short run during planned overreaching, when micro-trauma builds faster than the body can clear it.

The usual example is the final 4-6 week block before a powerlifting meet. Users describe a short, moderate-dose cycle here as a way to arrive at the platform sore rather than broken; no trial has looked at it. For anyone competing under the WADA Code, the 2026 Prohibited List bans BPC-157 (S0) and TB-500 (S2.3) at all times. Our page on the ethics of using peptides for recovery covers sport rules.

A commonly described mitigation protocol:

• When: During a planned high-volume or high-intensity training block (users typically cap it at 4-8 weeks).
• Peptides: BPC-157 alone in most reports.
• Dose reported: 250mcg once per day, sometimes twice on particularly brutal training days.

Users don't run this year-round; the point is to cover one specific, demanding period of training.

Listening to Your Tissue

These protocols are community guidelines, not laws or tested regimens. Their authors agree that feedback from your own body matters more than the schedule: if a tear feels 90% better after four weeks, nothing says an arbitrary eight-week plan must be finished. Users typically track pain and range of motion and adjust from there.

As of October 2026, no controlled human trial of BPC-157 has published results. Human safety data come from a few small pilots, such as a 2025 IV study in which two adults received 10 mg and then 20 mg with no side effects reported. Whether dose or injection site changes outcomes is untested. The overview of peptides and muscle recovery compares these two with growth hormone secretagogues.